Valuation: CalciMedica, Inc.

Market Cap 9.29M 8.33M 7.61M 6.95M 13.09M 873M 13.5M 91.75M 36.59M 466M 34.86M 34.11M 1.47B P/E 2026 *
-0.45x
P/E 2027 * -0.26x
Enterprise Value 9.29M 8.33M 7.61M 6.95M 13.09M 873M 13.5M 91.75M 36.59M 466M 34.86M 34.11M 1.47B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
81.47%
Yield 2026 *
-
Yield 2027 * -
1 day+4.62%
1 week-6.85%
Current month-6.85%
1 month-8.72%
3 months-61.80%
6 months-56.30%
Current year-95.87%
1 week 1.16
Extreme 1.1601
1.75
1 month 1
Extreme 1
1.84
Current year 1
Extreme 1
36
1 year 1
Extreme 1
36
3 years 1
Extreme 1
41.9
5 years 1
Extreme 1
42.95
10 years 1
Extreme 1
42.95
Manager TitleAgeSince
Chief Executive Officer 63 01/09/2019
Chief Tech/Sci/R&D Officer 73 01/04/2007
President 70 01/01/2014
Director TitleAgeSince
Chairman 85 20/03/2023
Chairman 63 -
Director/Board Member 54 20/03/2023
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Free

Director

20,000 0.2929%
01/10/26 Free

Director

20,000 0.2929%
01/10/26 Free

Director

20,000 0.2929%
Change 5-day change 1-year change 3-year change Capi.($)
+4.62%-6.85%-91.11%-91.50% 9.29M
-4.83%+3.51%+53.62%+61.75% 65.94B
-1.34%+2.98%+24.79%+100.18% 56.53B
+0.02%+1.07%+10.63%+76.66% 56.88B
+5.09%+9.89%+22.45%+107.48% 46.49B
+2.62%+1.68%+28.91%+37.01% 44.8B
+8.24%+0.51%+213.26%+792.66% 41.59B
-1.86%+10.13%+26.82%+53.22% 35.35B
-2.97%-9.84%+88.86%+76.17% 33.29B
-2.18%+7.06%+36.06%-4.95% 24.92B
Average +0.74%+2.64%+41.43%+120.87% 40.58B
Weighted average by Cap. +0.21%+3.40%+53.12%+142.95%

Financials

2026 *2027 *
Net sales - -
Net income -12.75M -11.43M -10.45M -9.54M -17.97M -1.2B -18.53M -126M -50.21M -639M -47.84M -46.81M -2.02B -27.1M -24.31M -22.22M -20.28M -38.21M -2.55B -39.42M -268M -107M -1.36B -102M -99.55M -4.29B
Net Debt - -
Projected Income Statement - Annual - CalciMedica, Inc.
Logo CalciMedica, Inc.
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
Employees
15
Date Price Change Volume
06/11/26 $1.360 +4.62% 20,568
05/11/26 $1.300 -3.35% 24,296
04/11/26 $1.345 -8.50% 43,708
03/11/26 $1.470 +5.00% 52,141
02/11/26 $1.400 -4.11% 164,958
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - CalciMedica, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.360USD
Average target price
38.00USD
Spread / Average Target
+2,694.12%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CalciMedica, Inc.
  1. Stock Market
  2. Stocks
  3. CALC Stock